Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.
Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma, which is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.
GlaxoSmithKline is seeking initial bids by mid-September for the company’s India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said.
As Shire’s acquisition by Takeda Pharmaceutical approaches, the global biotechnology company reported a solid second-quarter 2018.
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.
By Mark Terry The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal. Takeda originally planned to approach Shire’s board of directors about the acquisition on April 1, but published rumors […]
Roche and its subsidiaries are ramping up treatment options for multiple sclerosis. In April, the company acquired a regenerative therapy program for MS from Inception Sciences. Now, Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).
According to Reuters UK, Japan’s Takeda Pharmaceutical made an official bid to acquire London’s Shire for about $60 billion, which was rejected.
Veritas Capital to Acquire Revenue-Cycle, Ambulatory Care and Workforce Management Software Unit from GE Healthcare for $1 Billion
Veritas Capital, a leading private equity investment firm, and General Electric announced that an affiliate of Veritas entered into a definitive agreement with GE to acquire the Enterprise Financial Management (Revenue-Cycle, Centricity Business), Ambulatory Care Management (Centricity Practice Solution) and Workforce Management (formerly API Healthcare) assets comprising GE Healthcare’s Value-Based Care Division for $1.05 billion in cash.